Promising mesothelioma drug trial pulled before it even started
NCT ID NCT06654050
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the trial was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alrizomadlin (APG-115)
What this could lead to
If it works, this could point toward a treatment that slows or stops early mesothelioma growth in people with BAP1 cancer syndrome.
What could go wrong
The trial was withdrawn before enrolling anyone, so no results are available. It is unknown if the drug is safe or effective for this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States